Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Poissy

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Critical Care (London, England)|January 10, 2023
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, José R Arribas, Lambert Assoumou, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Critical Care (London, England)|January 10, 2023
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, José R Arribas, Lambert Assoumou, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 16, 2022
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesJérémy Manry, Paul Bastard, Adrian Gervais, et al.
Science Immunology|August 20, 2021
Autoantibodies neutralizing type I IFNs are present in <b>~</b>4% of uninfected individuals over 70 years old and account for <b>~</b>20% of COVID-19 deathsPaul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Pageof 9